Dashboard
Manage Tickers

IMVTImmunovant, Inc.

Nasdaq immunovant.com


$ 29.05 $ -0.67 (-2.25 %)    

Wednesday, 11-Sep-2024 15:59:55 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 467.92 $ -0.71 (-0.15 %)
DIA $ 410.06 $ 0.60 (0.15 %)
SPY $ 554.83 $ -0.16 (-0.03 %)
TLT $ 100.31 $ -0.06 (-0.06 %)
GLD $ 234.53 $ -0.11 (-0.05 %)
$ 29.05
$ 28.96 x 200
-- x --
-- - --
$ 19.50 - $ 45.58
910,435
na
4.25B
$ 1.30
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-06-2024 06-30-2024 10-Q
2 05-29-2024 03-31-2024 10-K
3 02-12-2024 12-31-2023 10-Q
4 11-09-2023 09-30-2023 10-Q
5 08-10-2023 06-30-2023 10-Q
6 05-22-2023 03-31-2023 10-K
7 02-03-2023 12-31-2022 10-Q
8 11-04-2022 09-30-2022 10-Q
9 08-05-2022 06-30-2022 10-Q
10 06-08-2022 03-31-2022 10-K
11 02-04-2022 12-31-2021 10-Q
12 11-05-2021 09-30-2021 10-Q
13 08-09-2021 06-30-2021 10-Q
14 06-01-2021 03-31-2021 10-K
15 02-16-2021 12-31-2020 10-Q
16 11-12-2020 09-30-2020 10-Q
17 08-12-2020 06-30-2020 10-Q
18 06-29-2020 03-31-2020 10-K
19 02-14-2020 12-31-2019 10-Q
20 11-13-2019 09-30-2019 10-Q
21 08-12-2019 06-30-2019 10-Q
22 06-12-2019 03-31-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

hc-wainwright--co-reiterates-buy-on-immunovant-maintains-51-price-target
HC Wainwright & Co. Reiterates Buy on Immu...
09/10/2024 11:15:21

HC Wainwright & Co. analyst Douglas Tsao reiterates Immunovant (NASDAQ:IMVT) with a Buy and maintains $51 price target.

cantor-fitzgerald-reiterates-overweight-on-immunovant
Cantor Fitzgerald Reiterates Overweight on...
09/09/2024 17:06:20

Cantor Fitzgerald analyst Louise Chen reiterates Immunovant (NASDAQ:IMVT) with a Overweight.

whats-going-in-with-vivek-ramaswamy-founded-roivant-sciences-stock-on-monday
What's Going In With Vivek Ramaswamy-Found...
09/09/2024 16:54:13

Immunovant reports promising Phase 2a trial results for batoclimab in treating Graves' Disease, showing a high response rat...

top-2-health-care-stocks-that-may-collapse-this-quarter
Top 2 Health Care Stocks That May Collapse...
09/09/2024 13:12:44

Core News & Articles
Roivant Says Immunovant Reported Results F...
09/09/2024 11:06:51

mmunovant also disclosed data from several proprietary market research studies that showed a consistent unmet need among ATD tr...

immunovant-reports-phase-2a-results-for-graves-disease-drug-fda-clears-pivotal-trial
Immunovant Reports Phase 2a Results for Gr...
09/09/2024 07:59:06

Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimm...

ubs-maintains-buy-on-immunovant-lowers-price-target-to-41
UBS Maintains Buy on Immunovant, Lowers Pr...
08/13/2024 14:42:38

UBS analyst Colin Bristow maintains Immunovant (NASDAQ:IMVT) with a Buy and lowers the price target from $42 to $41.

jp-morgan-maintains-overweight-on-immunovant-lowers-price-target-to-46
JP Morgan Maintains Overweight on Immunova...
08/08/2024 16:16:24

JP Morgan analyst Brian Cheng maintains Immunovant (NASDAQ:IMVT) with a Overweight and lowers the price target from $51 to $46.

cantor-fitzgerald-reiterates-overweight-on-immunovant
Cantor Fitzgerald Reiterates Overweight on...
08/07/2024 18:00:12

Cantor Fitzgerald analyst Louise Chen reiterates Immunovant (NASDAQ:IMVT) with a Overweight.

immunovant-q1-eps-060-misses-053-estimate
Immunovant Q1 EPS $(0.60) Misses $(0.53) E...
08/06/2024 21:11:30

Immunovant (NASDAQ:IMVT) reported quarterly losses of $(0.60) per share which missed the analyst consensus estimate of $(0.53) ...

cantor-fitzgerald-reiterates-overweight-on-immunovant
Cantor Fitzgerald Reiterates Overweight on...
06/20/2024 17:36:27

Cantor Fitzgerald analyst Louise Chen reiterates Immunovant (NASDAQ:IMVT) with a Overweight.

cantor-fitzgerald-reiterates-overweight-on-immunovant
Cantor Fitzgerald Reiterates Overweight on...
06/18/2024 14:06:18

Cantor Fitzgerald analyst Louise Chen reiterates Immunovant (NASDAQ:IMVT) with a Overweight.

oppenheimer-maintains-outperform-on-immunovant-lowers-price-target-to-46
Oppenheimer Maintains Outperform on Immuno...
06/03/2024 12:26:25

Oppenheimer analyst Leland Gershell maintains Immunovant (NASDAQ:IMVT) with a Outperform and lowers the price target from $5...

cantor-fitzgerald-reiterates-overweight-on-immunovant
Cantor Fitzgerald Reiterates Overweight on...
05/30/2024 15:47:36

Cantor Fitzgerald analyst Louise Chen reiterates Immunovant (NASDAQ:IMVT) with a Overweight.

hc-wainwright--co-reiterates-buy-on-immunovant-maintains-51-price-target
HC Wainwright & Co. Reiterates Buy on Immu...
05/30/2024 11:25:01

HC Wainwright & Co. analyst Douglas Tsao reiterates Immunovant (NASDAQ:IMVT) with a Buy and maintains $51 price target.

12-health-care-stocks-moving-in-wednesdays-after-market-session
12 Health Care Stocks Moving In Wednesday'...
05/29/2024 20:31:09

immunovant-q4-eps-052-misses-043-estimate
Immunovant Q4 EPS $(0.52) Misses $(0.43) E...
05/29/2024 20:05:36

Immunovant (NASDAQ:IMVT) reported quarterly losses of $(0.52) per share which missed the analyst consensus estimate of $(0.43) ...

biohaven-stock-stumbles-as-protein-degrading-drug-falls-short-of-expectations-in-early-stage-study
Biohaven Stock Stumbles As Protein-Degradi...
05/29/2024 18:47:15

Biohaven shares drop as interim data from the Phase 1 study of BHV-1300 fell short of investor expectations.

why-bank-of-montreal-shares-are-trading-lower-by-around-7-here-are-other-stocks-moving-in-wednesdays-mid-day-session
Why Bank of Montreal Shares Are Trading Lo...
05/29/2024 17:28:35

heico-posts-upbeat-earnings-joins-surmodics-abercrombie--fitch-and-other-big-stocks-moving-higher-on-wednesday
Heico Posts Upbeat Earnings, Joins Surmodi...
05/29/2024 14:38:24

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION